Hyperaldosteronemia as a risk factor of renal dysfunction in patients with heart failure with preserved ejection fraction

Cover Page


Cite item

Full Text

Abstract

Objective: To assess the relationship between plasma aldosterone levels and renal function in patients with heart failure with preserved ejection fraction (HFpEF).

Materials and methods: A cross-sectional study included 158 patients with confirmed HFpEF. Patients with primary hyperaldosteronism, edema syndrome, end stage renal disease and taking mineralocorticoid receptor antagonists were excluded. Renal function was assessed by determining daily urinary albumin excretion (UAE) and calculating the glomerular filtration rate (GFR). Plasma aldosterone was measured by enzyme immunoassay.

Results: The patients were divided into two groups: 99 patients had normal (40-160 pg/ml) aldosterone plasma level (nAld) and 59 patients had high (> 160 pg/ml) aldosterone level (hAld). hAld patients had significantly higher UAE (median 342 mg/day [interquartile value 253; 453] versus 116 mg/day [32; 255], p < 0.001), and lower GFR (52 ml/min/1.73 m2 [46; 67.5] versus 66 ml/min/1.73 m2 [53; 79]) compared to nAld. The prevalence of impaired renal filtration function and severe albuminuria was higher in hAld group then in nAld (p < 0.001). In binomial logistic regression models adjusted for age, severity of HFpEF and comorbidities high aldosterone plasma level were independent risk factors of significant (< 60 ml/min/1.73 m2) decrease in GFR (odds ratio 4.25, 95% confidence interval 2.01-16.6) and very high (> 300 mg/day) albuminuria (odds ratio 2.23, 95% confidence interval 1.24-9.63).

Conclusion: In HFpEF plasma aldosterone levels are closely related to renal function. Secondary hyperaldosteronism is associated with an increased risk of impaired renal filtration and severe albuminuria.

About the authors

A. N. Shevelok

М. Gorky Donetsk National Medical University; Institute of Urgent and Recovery Surgery named after V.K. Husak

Author for correspondence.
Email: a.shevelyok@mail.ru
ORCID iD: 0000-0001-6192-2576

Anna N. Shevelok - MD, PhD, Associate Professor, Chair of Internal Medicine No. 3 М. Gorky Donetsk NMU; Senior Research Fellow, Department of Cardiology and Cardiac Surgery IURS named after V.K. Husak

16 Il'icha prospekt, Donetsk, 283003, 47 Leninskiy prospekt, Donetsk, 283045; Tel.: +38 (062) 385 05 17

Ukraine

References

  1. Моисеев ВС, Мухин НА, Смирнов АВ, Кобалава ЖД, Бобкова ИН, Виллевальде СВ, Ефремовцева МА, Козловская ЛВ, Швецов МЮ, Шестакова МВ, Арутюнов ГП, Бойцов СА, Галявич АС, Гринштейн ЮИ, Добронравов ВА, Драпкина ОМ, Ермоленко ВМ, Карпов ЮА, Каюков ИГ, Котовская ЮВ, Кухарчук ВВ, Мартынов АИ, Морозова ТЕ, Оганов РГ, Подзолков ВИ, Рожинская ЛЯ, Терещенко СН, Фомин ВВ, Хирманов ВН, Чазова ИЕ, Шамхалова МШ, Шилов ЕМ, Шляхто ЕВ, Шутов АМ. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014;(8):7–37. doi: 10.15829/1560-4071-2014-8-7-37.
  2. Андрусев АМ, Томилина НА, Перегудова НГ, Шинкарев МБ. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014–2018 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества [Интернет]. Российское диализное общество. Регистр 2018. Доступно на: http://nephro.ru/index.php?r=site/pageView&id=298%20,%20journal.nephro.ru/index.php?r=journal/pageView&id=298.
  3. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226–34. doi: 10.1093/aje/kwn033.
  4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. doi: 10.1016/S0140-6736(13)60595-4.
  5. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112(10):1435–43. doi: 10.1161/CIRCULATIONAHA.105.539122.
  6. Levin A, Stevens PE, Bilous RW, Coresh J, Francisco ALMD, Jong PED, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak MG, Wang H, White CT, Winearls CG. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. doi: 10.1038/kisup.2012.73.
  7. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O'Connor CM, Zannad F, Pitt B. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013;167(5): 1677–87. doi: 10.1016/j.ijcard.2012.10.007.
  8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8. doi: 10.1016/j.jacc.2005.01.015.
  9. Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. doi: 10.1016/S2213-8587(17)30319-4.
  10. Карабаева АЖ. Альдостерон, сердечно-сосудистая система и почки. Нефрология. 2006;10(1):25–34. doi: 10.24884/1561-6274-2006-10-1-25-34.
  11. Карабаева АЖ, Каюков ИГ, Есаян АМ, Смирнов АВ. Ренин-ангиотензин-альдостероновая система при хронической болезни почек. Нефрология. 2006;10(4):43–8. doi: 10.24884/1561-6274-2006-10-4-43-48.
  12. Тащук ВК, Полянская ОС, Гулага ОИ. Влияние альдостерона на маркеры коллагенообразования у больных с инфарктом миокарда при почечной дисфункции. Запорожский медицинский журнал. 2018;4(20):467–70. doi: 10.14739/2310-1210.2018.4.135791.
  13. Wrenn SM, Vaidya A, Lubitz CC. Primary aldosteronism. Gland Surg. 2020;9(1):14–24. doi: 10.21037/gs.2019.10.23.
  14. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21(12):2143–9. doi: 10.1681/ASN.2010010085.
  15. Su WY, Wu PY, Huang JC, Chen SC, Chang JM. Increased Proteinuria is Associated with Increased Aortic Arch Calcification, Cardio-Thoracic Ratio, Rapid Renal Progression and Increased Overall and Cardiovascular Mortality in Chronic Kidney Disease. Int J Med Sci. 2020;17(8):1102–11. doi: 10.7150/ijms.45470.
  16. Márquez DF, Ruiz-Hurtado G, Segura J, Ruilope L. Microalbuminuria and cardiorenal risk: old and new evidence in different populations. F1000Res. 2019;8:F1000 Faculty Rev1659. doi: 10.12688/f1000research.17212.1.
  17. Mulè G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri D, Di Natale E, Cacciatore O, Cerasola G, Cottone S. Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. Adv Exp Med Biol. 2017;956:279–306. doi: 10.1007/5584_2016_85.
  18. Ren Q, Ma C, Wang J, Guo X, Ji L. Prevalence of Albuminuria in Cardiology and Endocrinology Departments and Its Influencing Factors: A Multicenter, Real-World Evidence Study in China. Int J Hypertens. 2020;2020:1231593. doi: 10.1155/2020/1231593.
  19. Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019;33(2):363–82. doi: 10.1111/jvim.15454.
  20. Ватутин НТ, Шевелёк АН, Дегтярева АЭ, Касем СС. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериальной гипертензии (обзор литературы). Журнал Національної академії медичних наук України. 2014;20(1):43–51.
  21. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63(5):1791–800. doi: 10.1046/j.1523-1755.2003.00929.x.
  22. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci. 2006;100(1):9–16. doi: 10.1254/jphs.fmj05003x3.
  23. Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci. 2008;108(4):399–405. doi: 10.1254/jphs.08r02cr.
  24. Кутырина ИМ, Крячкова АА, Савельева СА, Шестакова МВ. Роль альдостерона в поражении почек при метаболическом синдроме, ассоциированном с ожирением. Клиническая нефрология. 2010;(4):34–44.
  25. Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Björnson Granqvist A, Jaisser F, Huang Y, Granberg KL, Jansson-Löfmark R, Hartleib-Geschwindner J. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One. 2018;13(2):e0193380. doi: 10.1371/journal.pone.0193380.
  26. Asai M, Monkawa T, Marumo T, Fukuda S, Tsuji M, Yoshino J, Kawachi H, Shimizu F, Hayashi M, Saruta T. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res. 2004;27(12):971–8. doi: 10.1291/hypres.27.971.
  27. Barrera-Chimal J, Pérez-Villalva R, Ortega JA, Sánchez A, Rodríguez-Romo R, Durand M, Jaisser F, Bobadilla NA. Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration. Int J Biol Sci. 2015;11(8):892–900. doi: 10.7150/ijbs.11729.
  28. Spencer S, Wheeler-Jones C, Elliott J. Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease. J Vet Pharmacol Ther. 2020;43(3):243–67. doi: 10.1111/jvp.12848.
  29. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291(7):844–50. doi: 10.1001/jama.291.7.844.
  30. Kshirsagar AV, Bang H, Bomback AS, Vupputuri S, Shoham DA, Kern LM, Klemmer PJ, Mazumdar M, August PA. A simple algorithm to predict incident kidney disease. Arch Intern Med. 2008;168(22):2466–73. doi: 10.1001/archinte.168.22.2466.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Shevelok A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies